{"id":"NCT02065791","sponsor":"Janssen Research & Development, LLC","briefTitle":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","officialTitle":"A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-17","primaryCompletion":"2018-10-30","completion":"2018-10-30","firstPosted":"2014-02-19","resultsPosted":"2019-11-20","lastUpdate":"2019-12-05"},"enrollment":4401,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathy"],"interventions":[{"type":"DRUG","name":"Canagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).","primaryOutcome":{"measure":"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death","timeFrame":"Up to 4.6 years","effectByArm":[{"arm":"Placebo","deltaMin":61.24,"sd":null},{"arm":"Canagliflozin 100 mg","deltaMin":43.21,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":575,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","France","Germany","Guatemala","Hungary","India","Japan","Lithuania","Malaysia","Mexico","New Zealand","Philippines","Poland","Puerto Rico","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Arab Emirates","United Kingdom"]},"refs":{"pmids":["40689549","40658498","40526444","40375260","40239057","40105285","39844714","38932575","38770818","38401646","38240199","38099944","37876229","37872654","37671609","37603600","37438734","37345834","37120538","36999981","36889425","36302584","35938182","35929472","35063969","34029680","33874750","33826709","33619120","33554616","33358942","33340064","33263893","32930969","32354987","31707795","31291786","30990260","29253846"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":806,"n":2197},"commonTop":["Hypoglycaemia","Urinary Tract Infection","Hypertension","Blood Creatinine Increased","Oedema Peripheral"]}}